Back to Newsroom

Colin Goddard, Ph.D., Joins the Endocyte Board of Directors

WEST LAFAYETTE, Ind., Nov. 7, 2013 — Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that Colin Goddard, Ph.D. has joined Endocyte’s board of directors.